What Do Brewing, Brettanomyces and Biotech Have in Common?

By | June 19, 2017

The ISPE Boston Area Chapter kicked off the summer season with a standing-room-only event, “Brewing, Brettanomyces, and Biotech,” at Springdale Barrel Room by Jack’s Abby in Framingham.  This sold-out event was met with great anticipation and attendees did not leave disappointed.  The evening opened with a lively networking session with beer, food and great company. … Read More »

What Do BMWs and Validation Have in Common? Engi•dati•ty Assurance!

By | June 6, 2017

On May 17, the ISPE Boston Area Chapter joined the PDA New England Chapter for a combined ISPE/PDA dinner event under the banner “Validation: The Bridge Between Engineering & Quality Assurance” helmed by two superb presenters: Sylvan Poeckh of Masy BioServices and Paul Stanovich of Process Design Solutions. This topic was selected because effective validation… Read More »

When Good Bugs Go Bad – Contamination Detection in a Mixed Fermentation Brewery

By | June 5, 2017

Fermentation is a science dating back to the first known civilizations on this Earth, and has helped to shape the world as it is today. From bread and beer to sauerkraut and yogurt, fermentation has shaped cultures and traditions across the world. The vast diversity in fermentation is being rediscovered in the beer industry as… Read More »

Remembering Biotech Industry Pioneer Henri Termeer

By | June 1, 2017

Henri Termeer, one of the founding fathers of the biotech industry, died recently after collapsing in his Marblehead home. He led Genzyme from 1983 to 2011, the year Sanofi bought the company for more than $20 billion, and is credited with pioneering the much-imitated business model that would generate hundreds of medicines targeting rare diseases.… Read More »

Sanofi Pays ImmunoGen $30 Million in an Amended License Agreement

By | May 31, 2017

ImmunGen, which develops antibody-drug conjugates (ADCs) for the treatment of cancer, announced that it has amended its license agreements with Sanofi covering all compounds in development by Sanofi using ImmunoGen’s technology. Under the terms of the amended 2003 collaboration and license agreement, ImmunoGen has granted Sanofi a fully-paid, exclusive license to develop, manufacture, and commercialize… Read More »